Compare Stocks: LABT, KTTA, NCEL, and BCDA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$1.03 -1.0%	$1.02	$0.75 ▼ $1.80	$15.74M	0.55	353,764 shs	117,275 shs
KTTA Pasithea Therapeutics	$0.49 +2.1%	$0.51	$0.28 ▼ $2.06	$16.04M	0.33	178,648 shs	141,486 shs
LABT Lakewood-Amedex Biotherapeutics	$0.99 -13.9%	$2.17	$0.92 ▼ $98.20	$2.73M	N/A	2.37 million shs	1.24 million shs
NCEL NLS Pharmaceutics	$2.97 +1.7%	$3.32	$1.83 ▼ $22.40	$16.87M	0.94	5,227 shs	3,102 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	-0.96%	-1.90%	-10.43%	-13.45%	-26.43%
KTTA Pasithea Therapeutics	+2.08%	-4.69%	-12.50%	-13.57%	-30.99%
LABT Lakewood-Amedex Biotherapeutics	-13.93%	-50.26%	-56.97%	-70.01%	+98,979,900.00%
NCEL NLS Pharmaceutics	+1.71%	-2.30%	-6.90%	-22.86%	-87.88%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCDA BioCardia	$1.03 -1.0%	$1.02	$0.75 ▼ $1.80	$15.74M	0.55	353,764 shs	117,275 shs
KTTA Pasithea Therapeutics	$0.49 +2.1%	$0.51	$0.28 ▼ $2.06	$16.04M	0.33	178,648 shs	141,486 shs
LABT Lakewood-Amedex Biotherapeutics	$0.99 -13.9%	$2.17	$0.92 ▼ $98.20	$2.73M	N/A	2.37 million shs	1.24 million shs
NCEL NLS Pharmaceutics	$2.97 +1.7%	$3.32	$1.83 ▼ $22.40	$16.87M	0.94	5,227 shs	3,102 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCDA BioCardia	-0.96%	-1.90%	-10.43%	-13.45%	-26.43%
KTTA Pasithea Therapeutics	+2.08%	-4.69%	-12.50%	-13.57%	-30.99%
LABT Lakewood-Amedex Biotherapeutics	-13.93%	-50.26%	-56.97%	-70.01%	+98,979,900.00%
NCEL NLS Pharmaceutics	+1.71%	-2.30%	-6.90%	-22.86%	-87.88%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCDA BioCardia	2.00	Hold	$25.00	2,327.18% Upside
KTTA Pasithea Therapeutics	2.00	Hold	$3.00	512.24% Upside
LABT Lakewood-Amedex Biotherapeutics	1.00	Sell	N/A	N/A
NCEL NLS Pharmaceutics	2.00	Hold	$23.00	674.41% Upside

Current Analyst Ratings Breakdown

Latest LABT, KTTA, NCEL, and BCDA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/21/2026	KTTA Pasithea Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/18/2026	NCEL NLS Pharmaceutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/24/2026	BCDA BioCardia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	KTTA Pasithea Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/11/2026	BCDA BioCardia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
7/20/2026	LABT Lakewood-Amedex Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Sell (E-)
7/17/2026	BCDA BioCardia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	KTTA Pasithea Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold ➝ Strong-Buy
7/13/2026	NCEL NLS Pharmaceutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/13/2026	BCDA BioCardia	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
7/13/2026	NCEL NLS Pharmaceutics	Laidlaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$23.00

(Data available from 9/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCDA BioCardia	$60K	259.90	N/A	N/A	$0.08 per share	12.88
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	$2.39 per share	N/A
LABT Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A	N/A
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	$1.59 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCDA BioCardia	-$8.23M	-$0.64	N/A	N/A	N/A	N/A	-569.36%	-183.15%	11/11/2026 (Estimated)
KTTA Pasithea Therapeutics	-$20.43M	-$1.58	N/A	N/A	N/A	N/A	-49.49%	-46.81%	11/12/2026 (Estimated)
LABT Lakewood-Amedex Biotherapeutics	-$3.85M	-$4.75	N/A	0.75	N/A	N/A	N/A	N/A	N/A
NCEL NLS Pharmaceutics	-$8.30M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest LABT, KTTA, NCEL, and BCDA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/18/2026	Q2 2026	NCEL NLS Pharmaceutics	N/A	-$0.48	N/A	-$0.48	N/A	N/A
8/14/2026	Q2 2026	KTTA Pasithea Therapeutics	-$0.16	-$0.16	N/A	-$0.16	$0.30 million	N/A
8/14/2026	Q2 2026	LABT Lakewood-Amedex Biotherapeutics	N/A	-$2.75	N/A	-$2.75	N/A	N/A
8/12/2026	Q2 2026	BCDA BioCardia	-$0.18	-$0.13	+$0.05	-$0.13	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCDA BioCardia	N/A	N/A	N/A	N/A	N/A
KTTA Pasithea Therapeutics	N/A	N/A	N/A	N/A	N/A
LABT Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A	N/A	N/A
NCEL NLS Pharmaceutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCDA BioCardia	N/A	2.09	2.09
KTTA Pasithea Therapeutics	N/A	26.25	26.25
LABT Lakewood-Amedex Biotherapeutics	N/A	7.70	7.70
NCEL NLS Pharmaceutics	N/A	0.40	0.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCDA BioCardia	20.57%
KTTA Pasithea Therapeutics	23.92%
LABT Lakewood-Amedex Biotherapeutics	N/A
NCEL NLS Pharmaceutics	N/A

Insider Ownership

Company	Insider Ownership
BCDA BioCardia	17.40%
KTTA Pasithea Therapeutics	1.50%
LABT Lakewood-Amedex Biotherapeutics	5.35%
NCEL NLS Pharmaceutics	16.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCDA BioCardia	21	15.14 million	12.51 million	Optionable
KTTA Pasithea Therapeutics	5	33.41 million	32.91 million	Not Optionable
LABT Lakewood-Amedex Biotherapeutics	5	2.37 million	2.24 million	N/A
NCEL NLS Pharmaceutics	6	5.78 million	4.83 million	Not Optionable

LABT, KTTA, NCEL, and BCDA Headlines

Recent News About These Companies

NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes

September 28 at 8:00 AM | globenewswire.com

Der aktuelle Kurs der NewcelX AG Aktie beträgt 3,380.

August 27, 2026 | de.investing.com

NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing

July 31, 2026 | globenewswire.com

NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board

July 8, 2026 | globenewswire.com

NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes

July 1, 2026 | globenewswire.com

NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform

June 15, 2026 | globenewswire.com

NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes

May 27, 2026 | globenewswire.com

NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026

April 30, 2026 | globenewswire.com

Michel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) Stock

April 30, 2026 | insidertrades.com

NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference

April 20, 2026 | globenewswire.com

NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing

April 1, 2026 | globenewswire.com

NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes

March 9, 2026 | prnewswire.com

NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy

February 12, 2026 | prnewswire.com

NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences

January 29, 2026 | prnewswire.com

NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression

January 12, 2026 | prnewswire.com

NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board

January 5, 2026 | prnewswire.com

NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China

December 11, 2025 | prnewswire.com

NewCelX Appoints EY as New Auditor Following Merger

November 20, 2025 | tipranks.com

NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute

November 17, 2025 | prnewswire.com

NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board

November 6, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

LABT, KTTA, NCEL, and BCDA Company Descriptions

BioCardia NASDAQ:BCDA

$1.03 -0.01 (-0.96%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$1.03 +0.00 (+0.49%)

As of 09/29/2026 07:55 PM Eastern

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Pasithea Therapeutics NASDAQ:KTTA

$0.49 +0.01 (+2.08%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$0.47 -0.02 (-3.27%)

As of 04:00 AM Eastern

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications. The company intends to develop PAS-003, to treat amyotrophic lateral sclerosis; and PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Lakewood-Amedex Biotherapeutics NASDAQ:LABT

$0.99 -0.16 (-13.93%)

Closing price 09/29/2026 04:00 PM Eastern

Extended Trading

$0.98 -0.01 (-1.50%)

As of 04:02 AM Eastern

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide. The rapid rise of resistant pathogens has rendered many existing antibiotics ineffective against these pathogens, increasing the risk of severe infections, prolonged hospital stays, and substantial economic burdens. Despite this urgent need, the development of new antibiotics has slowed, with most advancements occurring within existing drug classes, leaving these new compounds vulnerable to resistance mechanisms. Our product candidates consist of antimicrobials targeting acute and chronic infectious diseases, which are delivered locally to the site of infection. As of March 2026, we hold 68 issued and 36 pending patent applications for our products and technologies, with coverage in major pharmaceutical markets. We have successfully completed our first exploratory human clinical trials for our lead product, the broad-spectrum Bisphosphocin® (anti-bacterial) Nu-3, which is being developed for the topical treatment of mildly infected diabetic foot ulcers (iDFU). We plan to conduct an initial Phase 2a safety and dose response study, followed by a placebo-controlled Phase 2b dose comparative study to identify the optimal dose for Phase 3 trials and eventual commercialization. This study will also determine the most appropriate administration regimen for Nu-3 gel formation in mildly infected diabetic foot ulcers. Additionally, we are advancing early-stage pipeline compounds and are focused on further characterizing them to identify the best clinical indications for non-clinical and clinical evaluation. Advancement of any of our product candidates to the commercialization stage is completely dependent on the outcome of clinical studies that are reviewed and approved by the FDA or other comparable regulatory authorities. Headquartered in University Park, Florida, we were originally incorporated in Delaware on July 11, 2006, under the name Nu Pharmas, Inc. (“Nu Pharmas”). We initially focused on antisense RNA research and the contract manufacturing of oligonucleotides. On April 9, 2007, Nu Pharmas acquired substantially all the assets of Renaissance Nutraceuticals, Inc., a Delaware corporation, and subsequently changed its name to Amedex Therapeutics, Inc. (“Amedex Therapeutics”). On November 11, 2007, Amedex Therapeutics acquired substantially all the assets of Lakewood Pharmaceuticals, Inc., a Delaware corporation. On February 1, 2008, Amedex Therapeutics changed its name to Lakewood-Amedex Inc. On June 5, 2025, the Company changed its name to Lakewood-Amedex Biotherapeutics Inc. and redomiciled as a Nevada corporation. Our corporate address is in University Park, Florida.

NLS Pharmaceutics NASDAQ:NCEL

$2.97 +0.05 (+1.71%)

As of 09/29/2026 03:59 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LABT, KTTA, NCEL, and BCDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LABT, KTTA, NCEL, and BCDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LABT, KTTA, NCEL, and BCDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LABT, KTTA, NCEL, and BCDA Company Descriptions

BioCardia NASDAQ:BCDA

Pasithea Therapeutics NASDAQ:KTTA

Lakewood-Amedex Biotherapeutics NASDAQ:LABT

NLS Pharmaceutics NASDAQ:NCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest LABT, KTTA, NCEL, and BCDA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest LABT, KTTA, NCEL, and BCDA Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

LABT, KTTA, NCEL, and BCDA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

LABT, KTTA, NCEL, and BCDA Company Descriptions

BioCardia NASDAQ:BCDA

Pasithea Therapeutics NASDAQ:KTTA

Lakewood-Amedex Biotherapeutics NASDAQ:LABT

NLS Pharmaceutics NASDAQ:NCEL

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools